CELLURIS
A pioneer in Brazil, Celluris acts to revolutionize cancer treatment through an innovative approach to immunotherapy, the CAR-T cell therapy or Chimeric Antigen Receptor T-cells Therapy. Clinical tests around the world are proving that the technique produces results never seen before for the treatment of hematological and solid tumors.
Celluris is the first company in Latin America to develop personalized treatment for cancer patients through CAR-T immunotherapy. This technique is based on the modification of the patient’s own cells into recognizing the tumor as a target, fighting it accurately.
DIFFERENTIALS
We are specialized in
cell therapy.
The first company to
develop CAR-T technology
in Brazil.
Therapies are tailored
to hematological and
solid tumors.
High
standards of bioethics.
TESTIMONIALS
“The goals of Celluris are pioneering for Brazil. The quest of implementing novel cancer therapies is of tremendous importance for the health and economy of all countries, however Brazil is only now finding its stride in the area of translational medicine. In this scenario, Celluris is a trail blazer, connecting innovation and the testing of these new approaches in patients. As such, Celluris is very well positioned to be one of the first proponents of CAR T cell therapy developed locally and, upon successful testing, may be one of the first startups established in Brazil to offer this sophisticated therapy commercially. Currently, Celluris has made great strides in its research pipeline and has a viable plan for the continuation of this important work. There has been critical progress at the laboratory bench and also critical partnerships have been established to promote the efforts of Celluris in Brazil and internationally. In all, Celluris is uniquely positioned to innovate in the area of CAR T cell therapy for a variety of cancers.“
